Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Arsenic trioxide
Drug ID BADD_D00169
Description Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide.
Indications and Usage For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL), and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression
Marketing Status Prescription
ATC Code L01XX27
DrugBank ID DB01169
KEGG ID D02106
MeSH ID D000077237
PubChem ID 14888
TTD Drug ID D07VIK
NDC Product Code 58621-001; 0220-0526; 76472-3004; 64757-0001; 50742-438; 70860-217; 43406-0318; 49315-007; 76472-1132; 70121-1483; 0220-0528; 0220-0553; 69918-720; 70121-1658; 62106-4878; 0220-0522; 68428-033; 64757-0016; 68428-083; 72659-245; 49315-005; 0220-0527; 70710-1610; 0220-0529; 0220-0530; 54973-0605; 54879-027; 43406-0168; 54875-0005; 0220-0525; 14789-600; 0220-0557; 68083-462; 63323-637; 0220-0550; 0220-0554; 0220-0549; 68382-997; 63459-601; 55150-366; 68428-225
Synonyms Arsenic Trioxide | As2O3 | Arsenous Anhydride | Diarsenic Trioxide | Arsenic Oxide (As2O3) | Arsenic(III) Oxide | Tetraarsenic Oxide | Arsenolite | As4O6 | Tetra-Arsenic Oxide | Tetra Arsenic Oxide | Tetraarsenic Hexaoxide | Arsenic Oxide (As4O6) | Tetra-Arsenic Hexaoxide | Tetra Arsenic Hexaoxide | Naonobin | Trisenox | Trixenox
Chemical Information
Molecular Formula As2O3
CAS Registry Number 1327-53-3
SMILES [O-2].[O-2].[O-2].[As+3].[As+3]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Cell deathApoptosis regulator BAXQ07812T89251Not Available
LeukopeniaCellular tumor antigen p53P04637T15739Not Available
LeukopeniaHeat shock 70 kDa protein 4P34932Not AvailableNot Available
LeukopeniaProtein c-FosP01100T28025Not Available
LeukopeniaHeat shock 70 kDa protein 1-likeP34931Not AvailableNot Available
Necrotising enterocolitis neonatalHeat shock protein HSP 90-alphaP07900T18477Not Available
Necrotising enterocolitis neonatalDnaJ homolog subfamily B member 1P25685T96704Not Available
Necrotising enterocolitis neonatal60 kDa heat shock protein, mitochondrialQ5ZL72Not AvailableNot Available
Necrotising enterocolitis neonatalHeat shock 70 kDa proteinP08106Not AvailableNot Available
Necrotising enterocolitis neonatalHeat shock protein beta-1Q00649Not AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Ecchymosis23.06.01.001; 01.01.03.001; 24.07.06.002--Not Available
Electrocardiogram abnormal13.14.05.001--Not Available
Electrocardiogram QT prolonged13.14.05.0040.004529%
Epistaxis24.07.01.005; 22.04.03.001--
Erythema23.03.06.001--Not Available
Eye disorder06.08.03.001--Not Available
Eye irritation06.04.05.003--Not Available
Eye pain06.08.03.002--
Eyelid oedema23.04.01.003; 10.01.05.001; 06.04.04.004--Not Available
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.003--
Facial paralysis17.04.03.0080.000799%Not Available
Fatigue08.01.01.002--
Febrile neutropenia08.05.02.004; 01.02.03.0020.000799%
Feeling abnormal08.01.09.014--Not Available
Femur fracture12.04.01.003; 15.08.03.0030.000533%Not Available
Fluid retention20.01.02.003; 14.05.06.0020.000533%Not Available
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Gamma-glutamyltransferase increased13.03.01.011--
Gastrointestinal disorder07.11.01.0010.000533%Not Available
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.001--Not Available
Gastrointestinal pain07.01.05.005--
Haemoglobin13.01.05.018--Not Available
Haemoptysis24.07.01.006; 22.02.03.004; 02.01.02.006--Not Available
Haemorrhage intracranial24.07.04.003; 17.08.01.0080.000208%
Headache17.14.01.0010.001598%
Hepatotoxicity12.03.01.008; 09.01.07.0090.001598%Not Available
Herpes simplex23.09.03.001; 11.05.02.001--Not Available
Herpes zoster23.09.03.002; 11.05.02.0030.000533%
Hyperbilirubinaemia14.11.01.010; 09.01.01.003; 01.06.04.003--Not Available
Hyperglycaemia14.06.02.002; 05.06.02.002--
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 8 Pages